Prostate cancer, a new targeted therapy after chemotherapy
[ad_1]
Expanding the use of a targeted oral drug for metastatic castration-resistant prostate cancer (mCRPC) in European Union countries. The European Commission has in fact approved olaparib, in combination with hormone therapy, for all patients for whom chemotherapy is no longer indicated. To date, however, in Italy it is reimbursed as monotherapy in patients with BRCA1/2 mutations (germinal or somatic), in progression after a previous hormonal therapy (which includes a new generation hormonal agent). “This new approval extends the use of olaparib to a larger group of patients, at an earlier stage and in combination with next-generation hormone therapy, regardless of the presence of BRCA mutations,” comments Joseph ProcopiusDirector of the Prostate Program and Genitourinary Medical Oncology IRCCS Foundation National Cancer Institute of Milan.
Cancers on the rise compared to 2020: over 14 thousand more cases in 2 years, lifestyle alarm
by Irma D’Aria
I study
The approval from the European Commission is based on results from the Phase III PROpel study, involving nearly 800 patients. In the trial, olaparib, combined with abiraterone and prednisone or prednisolone, reduced the risk of disease progression or death by 34% compared with abiraterone and prednisone or prednisolone alone. The median radiographic progression-free survival was 24.8 months for olaparib plus abiraterone versus 16.6 months for abiraterone alone. According to independent central review board analysis presented at the European Society of Medical Oncology (ESMO) Congress 2022, median progression-free survival reached 27.6 months, an increase of nearly a year over the previous year. studio arm. “The PROpel study demonstrated that, in patients with metastatic castration-resistant disease who had not received any other treatment previously, the addition of olaparib to abiraterone offers a significant benefit in terms of radiological progression-free survival,” Procopio points out. guaranteeing a good quality of life”.
Prostate cancer, here comes the help of precision medicine
by Sandro Iannaccone
Prostate cancer
Prostate cancer is the most common cancer in men in Europe and Italy. Overall survival for patients with metastatic castration-resistant disease is approximately three years in studies, and lower in clinical practice. “In 2022, 40,500 new diagnoses of prostate cancer were estimated in Italy – he says Sergio Bracarda, President of the Italian Society of Uro-Oncology (SIUrO) and Director of the Complex Structure of Medical and Translational Oncology and of the Oncology Department at the Santa Maria di Terni Hospital -. The impact of metastatic prostate cancer on the daily lives of patients who develop disease-related symptoms can be significant, in some cases limiting the ability to sleep or walk due to pain. There is a need for new treatment options for metastatic castration-resistant prostate cancer. Many patients with this form of cancer can only receive one line of active therapy, as the disease can progress rapidly.”
[ad_2]
Source link
